Arcturus Therapeutics Holdings Inc.

public$ARCT View Live Feed →

Total Raised

Contracts

$63,239,785

1 award of $10M+

Patents

PAC Giving

Government Contracts & Awards

ARCTURUS THERAPEUTICS, INC.: PROCURE A PANDEMIC INFLUENZA VACCINE (PANDFLU) AND A QUADRIVALENT SEASONAL INFLUENZA VACCI

$63,239,785

Award Office of Assistant Secretary for Preparedness and Response Aug 31, 2022

Proprietary Tech & Patents

No patents found in our USPTO sample (a narrow, keyword-clustered feed of recent grants in strategic tech sectors — not a comprehensive patent database).

Form D Funding

No recent SEC Form D filings found.

Market Intelligence & News

Yahoo Aug 12, 2026

Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline

Arcturus Therapeutics (NASDAQ:ARCT) is positioning its mRNA platform around two rare-disease programs targeting cystic fibrosis and ornithine transcarbamylase deficiency, while its vaccine business is intended to help support therapeutic development, President and CEO Joseph Payne said during a Cana

Congressional Trades in $ARCT

No disclosed congressional trades found in $ARCT.

Insider Trades (Form 4)

Factual Connections

Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.

Upgrade to Pro